Feprazone: absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects.
Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically significant changes of hematologic tests were observed.
D000293:Adolescent; D000328:Adult; D004912:Erythrocytes / Q000187:drug effects; D011298:Feprazone / Q000009:adverse effects / Q000494:pharmacology*; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood*; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D011298:Feprazone; D010653:Phenylbutazone